Camrelizumab in combination with chemotherapy versus concurrent chemoradiotherapy for the conversion of locally advanced unresectable oesophageal squamous carcinoma: protocol for a two-arm, open-label phase II trial
Introduction Oesophageal cancer (OC) has higher morbidity and mortality rate than most other malignancies. The standard treatment for unresectable locally advanced oesophageal squamous cell carcinoma (OSCC) is concurrent chemoradiotherapy, with tumour regression observed in a proportion of patients...
Main Authors: | Chun Chen, Bin Zheng, Maohui Chen, Yizhou Huang, Shuliang Zhang, Yixiong Zheng, Taidui Zeng |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-02-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/14/2/e075421.full |
Similar Items
-
Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a prospective single-arm phase II clinical trial protocol
by: Maohui Chen, et al.
Published: (2023-08-01) -
Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study
by: Rui-Qin Zhou, et al.
Published: (2023-05-01) -
Camrelizumab, chemotherapy and apatinib in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: a single-arm phase 2 trialResearch in context
by: Zixiang Wu, et al.
Published: (2024-05-01) -
Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer
by: Baihua Zhang, et al.
Published: (2023-02-01) -
Comparing concurrent chemoradiotherapy, 125I seed implantation combined with chemotherapy, and chemotherapy alone efficacy in treating unresectable locally advanced pancreatic cancer
by: Yanfen Zheng, et al.
Published: (2022-06-01)